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Introduction: The aim of the study is to investigate whether standard doses of rosiglitazone 
(4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly 
diagnosed never treated type 2 diabetes (T2DM) patients.
Methods: In this randomized, double-blind, placebo-controlled study, 33 T2DM patients were 
randomized to rosiglitazone (4 mg/daily) or ramipril (5 mg/daily) or placebo for 1 year. Hemo-
dynamic variables were measured at 3 treatment phases and pulse wave velocity (PWV) and 
augmentation index (AI) were measured throughout the treatment period.
Result: In diabetic patients, PWV (P = 0.037) and AI (P = 0.005) with ramipril and AI 
(P  0.001) with rosiglitazone were significantly reduced during overall treatment period from 
the baseline; however, these differences were not significant in comparison to placebo.
Discussion and conclusion: The present study showed that treatment with standard doses of 
rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. The 
lack of benefit in newly diagnosed T2DM may be because of the relatively short-term interven-
tion and/or the use of lower doses of rosiglitazone/ramipril. Further trials are needed for a longer 
period of time, possibly with higher doses, to show whether rosiglitazone/ramipril can reverse 
pre-clinical vasculopathy in T2DM (ClinicalTrials.gov number, NCT00489229).
Keywords: rosiglitazone, ramipril, diabetic vasculopathy
Patients with type 2 diabetes (T2DM) have an increased risk of macrovascular com-
plications compared with the general population.1 Diabetic macrovascular disease is 
the commonest cause of morbidity and mortality and is responsible for high incidence 
of vascular diseases such as stroke, myocardial infarction and peripheral vascular 
diseases.2 In macrovascular diseases, pathophysiological changes in the arterial wall 
lead to structural and functional changes in the large arteries which cause increased 
stiffness, abnormal pulse wave travel and increased systolic hypertension. Diabetes 
complications can be controlled and avoided by strict glycemic control, maintaining 
normal lipid profiles, regular physical exercise, adopting a healthy lifestyle and phar-
macological interventions. Treatment goals for T2DM specify targets for glycemia 
and other cardiometabolic risk factors, eg, hypertension and dyslipidemia. In recent 
years, special interest has been developed in the use of thiazolidinediones (TZDs) 
(eg, rosiglitazone,3,4 piolitazone5,6) and angiotensin converting enzyme (ACE) inhibi-
tors (eg, ramipril,7 enalapril,8,9 perindopril10) to treat diabetic macrovasculopathy. To 
date, a few studies had been conducted on T2DM to investigate the pharmacological Clinical Pharmacology: Advances and Applications 2010:2 84
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actions of rosiglitazone3,4 and ramipril7 on arterial stiffness. 
The aim of our study was to investigate whether standard 
doses of rosiglitazone and ramipril can reverse pre-clinical 
macrovasculopathy in newly diagnosed never treated T2DM 
patients.
Methods
Subjects
A preliminary screening of 1620 subjects was conducted in 
hospital and other community-settings from October 2002 
to October 2004.11,12 Participants were 30 to 65 years of age, 
newly diagnosed never treated (no antidiabetic, antihyperten-
sive, lipid lowering agents or any other medication) T2DM 
patients, non-obese (BMI  30 kg/m2), non-smoker, non-
hyperlipidemic (total cholesterol 7.8 mmol/L), no previous 
history of micro- and macrovascular complications, and no 
atrial fibrillation. Known diabetic and hypertensive cases 
were excluded. Out of 1620, 644 met the study criteria and 
had oral glucose tolerance test (OGTT). Thirty-three patients 
were included who met the study criteria. The research pro-
tocol was approved by the research and ethics committee of 
Universiti Sains Malaysia.
Research strategy
Randomization
The patients were randomized into 3 treatment groups 
(11 in each group) and randomly assigned to either rosigli-
tazone (4 mg), or ramipril (5 mg), or placebo. The treatment 
assignment was randomly distributed among each group of 
patients by block randomization. The process of randomiza-
tion was carried out between 2002 and 2005.
Measurement and follow up
Total follow up period was 1 year, comprising 9 visits – 1st 
(week 1, week 2, week 4), 3rd, 5th, 7th, 9th, 11th and 
12th month. The follow-up of all the patients was com-
pleted by 2005. Hemodynamic variables were measured at 
3 treatment phases (1st [week 1], 7th and 12th month) and 
arterial stiffness was measured at every visit. Arterial stiff-
ness (pulse wave velocity [PWV] and augmentation index 
[AI]) was assessed by SphygmoCor® (PWV Medical Pty. 
Australia) and details were described elsewhere.11,12 The 
power to demonstrate the differences in arterial stiffness 
between groups was at 80% and alpha of 0.05 (2 tailed) 
and the coefficient of variance for PWV was 3.12 m/s and 
for AI 2.93%.
Data analysis
Statistical analysis was performed using SPSS for windows 
(version 11.5). Data are expressed as mean ± standard 
deviation. Repeated measure analysis of variance was 
applied to determine the between group changes of PWV 
and AI at 1st (week 1, week 2, week 4), 3rd, 5th, 7th, 9th, 
11th and 12th month after drugs were started. Within group 
changes were analyzed by using multiple paired t-test 
method. Week 1 (month 1) was considered as the baseline 
of the study. P value was compared with the α-Bonferroni 
correction, which was found to be 0.0013. Test results 
for treatment group effects were considered significant as 
P value  0.05.
Results
Among diabetes subjects, a total of 10 (91%) in the rosi-
glitazone, 11 (100%) in ramipril and 10 (91%) in placebo 
group completed the study. In diabetic patients, PWV 
(P = 0.037) and AI (P = 0.005) with ramipril and AI 
(P  0.001) with rosiglitazone were significantly reduced 
during overall treatment period from the baseline (Figure 1); 
however, these differences were not significant in compari-
son to placebo (Table 1). A significant decrease in 2-hour 
postprandial glucose (P  0.001) and total cholesterol 
(P = 0.025) and significant increase in low-density lipopro-
tein (LDL) (at month 7, P = 0.02) were demonstrated within 
rosiglitazone treatment group from the baseline. Ramipril 
group showed significant reduction in 2-hour postprandial 
glucose (P = 0.007) and LDL (P = 0.011) throughout study 
period; however, these changes were not significant in 
comparison to placebo (Table 1).
The use of standard doses of rosiglitazone (4 mg/day) 
and ramipril (5 mg/day) were found to have less serious 
side-effects. There was a small weight gain (0.43% from 
baseline) in T2DM patients with rosiglitazone treatment but 
it was not statistically significant compared to placebo. Six 
diabetic patients had average of 1.75 kg weight gain with 
rosiglitazone. Most importantly, no patient suffered from 
myocardial infraction, congestive cardiac failure or died 
due to cardiovascular causes in this group as reported in a 
published meta-analysis.13 This may be due to the absence 
of any cardiovascular diseases/risk factors in this particular 
patient group who were much younger (47 years), drug 
naïve and newly diagnosed diabetic patients. One patient 
experienced mild cough (tolerable irritation) with ramipril 
during treatment period; however, the symptom subsided 
without any treatment.Clinical Pharmacology: Advances and Applications 2010:2 85
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Discussion and conclusion
The present study is the first to investigate the effect of rosi-
glitazone and ramipril on arterial stiffness in newly diagnosed 
never treated T2DM patients without any cardiovascular (CV) 
complication using strict inclusion and exclusion criteria. 
Although the treatments showed a significant change in 
preclinical vasculopathy from the baseline, but could not find 
any difference in comparison to placebo. The main reason 
why diabetic patients failed to show any changes may be due 
to shorter duration of intervention3,8,10 and/or lower dose of 
the drugs.14 The much-developed vasculopathy in established 
diabetes may need intervention for a longer period of time7,15 
and/or the use of higher doses of rosiglitazone (8 mg)16 and 
ramipril (10 mg).7,15
The rationale of using standard dose of rosiglitazone 
4 mg/day was found to be effective in controlling biochemical 
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Figure 1 Estimated marginal means of PWV and AI in type 2 diabetes between treatment with rosiglitazone, ramipril and placebo from base line overtime. With ramipril PWV 
(P = 0.037) and AI (P = 0.005) and with rosiglitazone AI (P  0.001) were significantly reduced during overall treatment period from the baseline.
Abbreviations: AI, augmentation index; PWV, pulse wave velocity.
Table 1 Changes in hemodynamic and biochemical parameters following treatment in type 2 diabetes
Parameters 
 
Rosiglitazone Ramipril Placebo
Baseline Treated Baseline Treated Baseline Treated
BMI (kg/m2) 26.6 ± 1.4 26.8 ± 1.2 26.7 ± 4.3 26.1 ± 4.4 27.0 ± 3.2 27.0 ± 3.3
SBP (mmHg) 126.6 ± 9.2 125.1 ± 9.9 123.1 ± 11.4 116.5 ± 14.8 130.5 ± 6.2 120.6 ± 10.9
DBP (mmHg) 77.0 ± 6.9 74.8 ± 9.1 75.6 ± 6.0 69.0 ± 9.1 80.4 ± 6.8 75.8 ± 6.4
HR (bpm) 67.7 ± 16.4 70.4 ± 9.0 66.6 ± 7.8 68.1 ± 8.5 70.5 ± 11.6 71.9 ± 10.5
FBS (mmol/L) 8.4 ± 3.4 6.8 ± 1.9 8.6 ± 3.0 7.4 ± 2.5 9.2 ± 3.7 7.9 ± 2.1
2hPPG (mmol/L) 14.6 ± 3.6 9.8 ± 3.7* 14.6 ± 5.1 11.9 ± 5.3** 15.4 ± 4.8 14.0 ± 2.8
HbA1c (%) 7.5 ± 1.7 6.3 ± 2.6 7.3 ± 2.1 6.7 ± 1.5 8.3 ± 2.3 7.1 ± 1.3
FI (ulU/mL) 10.6 ± 5.6 9.6 ± 5.1 9.3 ± 5.0 9.1 ± 4.7 7.6 ± 3.3 7.5 ± 2.9
HDL (mmol/L) 1.4 ± 0.4 1.5 ± 0.6 1.3 ± 0.1 1.3 ± 0.2 1.3 ± 0.3 1.2 ± 0.2
LDL (mmol/L) 3.6 ± 0.6 4.0 ± 0.6* 4.0 ± 1.2 3.1 ± 1.0* 3.7 ± 1.4 3.9 ± 1.0
TG (mmol/L) 1.8 ± 0.8 1.5 ± 1.1 1.3 ± 0.5 1.2 ± 0.7 1.8 ± 0.9 2.0 ± 0.9
TChol (mmol/L) 5.9 ± 0.9 5.4 ± 1.1** 5.8 ± 0.8 5.5 ± 0.8 5.9 ± 1.4 6.5 ± 3.1
AI (%) 131.7 ± 18.9 119.6 ± 13.9* 141.9 ± 17.8 130.3 ± 13.9** 132.8 ± 15.0 131.1 ± 11.7
PWV (m/s) 9.6 ± 2.2 8.5 ± 0.9 10.7 ± 3.5 8.7 ± 1.6* 10.1 ± 1.9 9.4 ± 2.1
Notes: Values are means ± standard deviation (SD); P values are based on analysis of variance (ANOVA). *P  0.001, **P  0.05.
Abbreviations: AI, augmentation index; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; FBS, fasting blood sugar;   
2hPPG, 2-h postprandial glucose; HbA1c, glycated hemoglobin; FI, fasting insulin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TChol, total cho-
lesterol; PWV, pulse wave velocity.Clinical Pharmacology: Advances and Applications 2010:2 86
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parameters of diabetes in most of the previous clinical 
trials.17,18 Thiazolidinediones are found to be most effec-
tive when used with the earliest form of diabetes and also 
in the drug naïve patients when insulin secretion is still 
substantial.19–21 Phillips et al17 recommend that once-daily 
dose (4 mg) may be sufficient as first-line therapy for patients 
with recent diagnoses, and 4 mg twice daily for patients 
with more advanced diabetes. Our study demonstrated a 
clear trend of decreasing PWV , AI and other hemodynam-
ics variables throughout the study period (significant with 
baseline, Table 1), though the changes were not significant in 
comparison to placebo. The reason of insignificant improve-
ment may be that large arteries have a major component of 
fixed fibrotic tissue which probably needs more time for 
‘tissue repair’ in much developed vasculopathy in patients 
with T2DM.3 Shargorodsky et al3 increased the dose from 
4 mg/daily dose to 8 mg/daily after 3-month treatment in 
patients who had hemoglobin A1c level  9% and contin-
ued for further 3 months. However, they failed to show any 
changes in large artery stiffness in T2DM with increased 
dose. Pistrosch et al4 demonstrated that rosiglitazone (4 mg 
twice daily) had therapeutic effects on endothelial dysfunc-
tion in T2DM (n = 12) patients in a 12-week double blind 
cross-over study. From this evidence, it may be suggested 
that higher dose of rosiglitazone is needed for longer duration 
to reverse the preclinical macrovasculopathy.
The present study is the first to conduct a clinical trial with 
standard dose of ramipril (5 mg daily) to examine its effects 
on arterial stiffness. Previous studies used 1.25 mg/day,14 
2.5 mg/day7 or 10 mg/day7 to study the cardioprotective 
effects in patients with T2DM. However, 1.25 mg/day and 
2.5 mg/day failed to show any effect on CV outcomes. The 
SECURE study also showed a strong dose dependency 
of atherosclerosis progression, with highest benefit in the 
ramipril 10 mg/day study group than 2.5 mg/day group.7 
Ramipril 10 mg/day was also the dose used in the HOPE 
trial, where it had very clear benefits on a range of clinical 
end points. The absence of CV protection with standard 
dose of ramipril in our study may suggest that a higher dose 
is required to reverse the macrovasculopathy in diabetes 
patients.
The present study is also the first to conduct a clinical trial 
with 1-year duration to examine the effects of ramipril on 
diabetic vasculopathy. Previous short-term studies (12 week 
to 6 months) on diabetes8,10 and hypertensive patients22,23 
investigated effectiveness of ACE inhibitors on arterial stiff-
ness could not definitively establish therapeutic efficacy. In a 
recent study, Kaiser et al8 compared the effects of a β-blocker 
(nebivolol) with an ACE inhibitor (enalapril) on parameters 
of insulin sensitivity, peripheral blood flow and arterial 
stiffness in T2DM patients assessing PWV and AI using 
SphygmoCor. No differences between nebivolol and enala-
pril were observed on any of above mentioned parameters. 
The authors suggested larger scale clinical trials with a longer 
treatment duration to investigate hard clinical endpoints in 
hypertensive T2DM patients. Another study24 examined the 
effect of angiotensin-converting enzyme (ACE) inhibitors 
(perindopril) on arterial stiffness for 7 months and suggested 
that high doses of ACE inhibitors, administered for a long 
period of time, are required in hypertensive T2DM patients 
to obtain a marked inhibition of the renin–angiotensin system 
and to reduce carotid stiffness.
In contrast, long-term studies7,9,15 established car-
dioprotective effects of ramipril in patients with T2DM. 
The SECURE, and MICRO-HOPE studies conducted for 
4.5 years showed clear benefits of ramipril on CV end points. 
Bosch et al25 reported that prolonged use of ramipril prevents 
incidence of stroke in patients with vascular diseases and 
diabetes, followed for 4.5 years as part of the HOPE study. 
A study conducted by Hosomi et al9 demonstrated long-
term treatment (2 years) with an ACE inhibitor (enalapril) 
and confirmed that ‘age-related’ and ‘diabetic-associated’ 
atherosclerosis was slowed down by chronic treatment for 
a period of 2 years. In their study systolic blood pressure 
(SBP) decreased on average by 4.8 mmHg during the first 
year and was maintained at the same level during the second 
year. The author speculated that decreased SBP during the 
first period may slightly constrict the common carotid artery 
and may transiently increase the apparent intima-media thick-
ness (IMT), which may in turn decrease the wall tension and 
eventually slow the rate of IM thickening. It is suggested that 
a minimum 2-year treatment period is needed to evaluate 
therapeutic efficacy on IMT and to exclude possible early 
(up to 1 year) confounding of transient or apparent effects due 
to decreased SBP. Intra-group analysis in our study showed 
mean reduction of 6.64 mmHg in SBP in T2DM patients and 
this suggests long-term treatment (2 years) with ramipril to 
demonstrate significant improvement in arterial stiffness.
Considering all this evidence, it can be emphasized that 
treatment with ramipril needs higher doses (10 mg or more) 
and longer treatment (2 years) and this is confirmed by 
SECURE and DIABHYCAR studies. The SECURE study 
showed improvement of arterial stiffness with higher doses 
(10 mg/day, not with 2.5 mg/day) for a treatment of 4.5 years 
and on the other hand DIABHYCAR study failed to show any 
improvement with 1.25 mg/day for a period of 2.5 years.Clinical Pharmacology: Advances and Applications 2010:2
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As the studies with rosiglitazone and ramipril on arterial 
stiffness are very limited, further randomized controlled trials 
should be undertaken for a longer period of time, possibly 
with higher doses, to show whether rosiglitazone and ramipril 
can reverse pre-clinical macrovasculopathy in T2DM.
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